Glaukos Corporation (GKOS) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY26 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Glaukos Corporation (GKOS) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY26 Revenue Guidance

Glaukos Announces Second Quarter 2026 Financial Results

July 29, 2026 4:05 PM EDT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include:

Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis. Glaucoma record net sales of $155.2 million in Q2 2026 increased 50% year-over-year. U.S. Glaucoma record net sales of $118.5 million in Q2 2026 increased 64% year-over-year. Gross... More